| Wendy Davis, PHARMD | |
|
445 Putnam Pike, Greenville, RI 02828-2430 | |
| (401) 231-5320 | |
| (401) 231-8547 |
| Full Name | Wendy Davis |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 445 Putnam Pike, Greenville, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477120327 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH04442 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Wendy Davis, PHARMD 323 Town Farm Rd, Pascoag, RI 02859-2412 Ph: (401) 309-7094 | Wendy Davis, PHARMD 445 Putnam Pike, Greenville, RI 02828-2430 Ph: (401) 231-5320 |
News Archive
In Florida, the state hospital association is pressing for a cost-benefit analysis before lawmakers take a final vote on Medicaid expansion, and in Ohio, GOP lawmakers leave the door open for a move later this year.
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.
The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.
Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors.
Johnson & Johnson and Elan Corporation plc today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP).
› Verified 2 days ago
Alexis M Bolvin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 | |
Mr. David G Saccoccio, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 446 Putnam Pike, Greenville, RI 02828 Phone: 401-949-1848 | |
Debra A Archetto, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 Fax: 401-949-6217 | |
Dr. Nicholas G Brunelle, PHARM.D., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 446 Putnam Pike, Greenville, RI 02828 Phone: 401-949-1848 Fax: 401-949-1539 | |
Adam Dinitto, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 | |
Mr. Robert Poholek, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 Fax: 401-949-6217 |